The 8 references in paper И. Явелов С., И. Явелов С. (2015) “КАРДИОВЕРСИЯ ПРИ ИСПОЛЬЗОВАНИИ РИВАРОКСАБАНА У БОЛЬНЫХ С НЕКЛАПАННОЙ ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ: РЕЗУЛЬТАТЫ ИССЛЕДОВАНИЯ X-VERT” / spz:neicon:aterotromboz:y:2015:i:1:p:24-30

1
Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran Versus Warfarin in Patients With Atrial Fibrillation. An Analysis of Patients Undergoing Cardioversion. Circulation,
(check this in PDF content)
2
11, 123: 131–136. 2. Piccini JP, Stevens SR, Lokhnygina Y et al., for the ROCKET AF Steering Committee & Investigators. Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. JACC, 2013, 61: 1998–2006.
(check this in PDF content)
3
Flaker G, Lopes RD, Al-Khatib SM et al. Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation Insights From the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). JACC, 2014, 63: 1082–1087.
(check this in PDF content)
4
Guidelines for the management of atrial fibrillation.The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J, 2010, 31: 2369–2429.
(check this in PDF content)
5
2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012, 33, 2719–2747.
(check this in PDF content)
6
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. A Report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. JACC, 2014, 64: e1–e76.
(check this in PDF content)
7
Ezekowitz MD, Cappato R, Klein AL et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with doseadjusted vitamin K antagonists in patientswith nonvalvular atrial fibrillation undergoing elective cardioversion. Am Heart J, 2014, 167: 646–52.
(check this in PDF content)
8
Cappato R, Ezekowitz MD, Klein AL et al., on behalf of the X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J,2014, 35: 3346–3355.
(check this in PDF content)